| 21.64 0 (0%) | 02-13 09:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 25.41 | 1-year : | 29.68 |
| Resists | First : | 21.76 | Second : | 25.41 |
| Pivot price | 21.59  |
|||
| Supports | First : | 21.56 |
Second : | 21.45 |
| MAs | MA(5) : | 21.63 |
MA(20) : | 21.57 |
| MA(100) : | 19.81 |
MA(250) : | 14.04 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 53.2 |
D(3) : | 56.7 |
| RSI | RSI(14): 61.5 | |||
| 52-week | High : | 23.56 | Low : | 6.38 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AVDL ] has closed below upper band by 24.5%. Bollinger Bands are 93.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 41 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 21.66 - 21.76 | 21.76 - 21.85 |
| Low: | 21.37 - 21.49 | 21.49 - 21.61 |
| Close: | 21.44 - 21.63 | 21.63 - 21.81 |
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.
Thu, 16 Jul 2026
Avadel Pharmaceuticals (AVDL) Jefferies London Healthcare Conference 2024 Summary - Quartr
Wed, 15 Jul 2026
Avadel Pharmaceuticals (AVDL) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
Wed, 15 Jul 2026
Avadel Pharmaceuticals (AVDL) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr
Wed, 08 Jul 2026
Avadel Pharmaceuticals (AVDL) Morgan Stanley 23rd Annual Global Healthcare Conference summary - Quartr
Mon, 16 Feb 2026
Avadel Pharmaceuticals plc acquired by Alkermes plc - Arthur Cox LLP
Thu, 12 Feb 2026
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 98 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 86.8 (%) |
| Shares Short | 2,310 (K) |
| Shares Short P.Month | 2,730 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1 |
| Profit Margin | -0.2 % |
| Operating Margin | 2.5 % |
| Return on Assets (ttm) | -0.4 % |
| Return on Equity (ttm) | -0.4 % |
| Qtrly Rev. Growth | 54.9 % |
| Gross Profit (p.s.) | 2.4 |
| Sales Per Share | 2.53 |
| EBITDA (p.s.) | 0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 35 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 21.42 |
| Price to Sales | 8.54 |
| Price to Cash Flow | 61.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|